Cargando…
ENLIST 1: An International Multi-centre Cross-sectional Study of the Clinical Features of Erythema Nodosum Leprosum
Erythema nodosum leprosum (ENL) is a severe multisystem immune mediated complication of borderline lepromatous leprosy and lepromatous leprosy. ENL is associated with skin lesions, neuritis, arthritis, dactylitis, eye inflammation, osteitis, orchitis, lymphadenitis and nephritis. The treatment of EN...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4564249/ https://www.ncbi.nlm.nih.gov/pubmed/26351858 http://dx.doi.org/10.1371/journal.pntd.0004065 |
_version_ | 1782389405500047360 |
---|---|
author | Walker, Stephen L. Balagon, Marivic Darlong, Joydeepa Doni, Shimelis N. Hagge, Deanna A. Halwai, Vikas John, Annamma Lambert, Saba M. Maghanoy, Armi Nery, Jose A. C. Neupane, Kapil D. Nicholls, Peter G. Pai, Vivek V. Parajuli, Pawan Sales, Anna M. Sarno, Euzenir Shah, Mahesh Tsegaye, Digafe Lockwood, Diana N. J. |
author_facet | Walker, Stephen L. Balagon, Marivic Darlong, Joydeepa Doni, Shimelis N. Hagge, Deanna A. Halwai, Vikas John, Annamma Lambert, Saba M. Maghanoy, Armi Nery, Jose A. C. Neupane, Kapil D. Nicholls, Peter G. Pai, Vivek V. Parajuli, Pawan Sales, Anna M. Sarno, Euzenir Shah, Mahesh Tsegaye, Digafe Lockwood, Diana N. J. |
author_sort | Walker, Stephen L. |
collection | PubMed |
description | Erythema nodosum leprosum (ENL) is a severe multisystem immune mediated complication of borderline lepromatous leprosy and lepromatous leprosy. ENL is associated with skin lesions, neuritis, arthritis, dactylitis, eye inflammation, osteitis, orchitis, lymphadenitis and nephritis. The treatment of ENL requires immunosuppression, which is often required for prolonged periods of time and may lead to serious adverse effects. ENL and its treatment is associated with increased mortality and economic hardship. Improved, evidence-based treatments for ENL are needed; however, defining the severity of ENL and outcome measures for treatment studies is difficult because of the multiple organ systems involved. A cross-sectional study was performed, by the members of the Erythema Nodosum Leprosum International STudy (ENLIST) Group, of patients with ENL attending seven leprosy referral centres in Brazil, Ethiopia, India, Nepal, the Philippines and the United Kingdom. We systematically documented the clinical features and type of ENL, its severity and the drugs used to treat it. Patients with chronic ENL were more likely to be assessed as having severe ENL. Pain, the most frequent symptom, assessed using a semi-quantitative scale was significantly worse in individuals with “severe” ENL. Our findings will determine the items to be included in a severity scale of ENL which we are developing and validating. The study also provides data on the clinical features of ENL, which can be incorporated into a definition of ENL and used for outcome measures in treatment studies. |
format | Online Article Text |
id | pubmed-4564249 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-45642492015-09-17 ENLIST 1: An International Multi-centre Cross-sectional Study of the Clinical Features of Erythema Nodosum Leprosum Walker, Stephen L. Balagon, Marivic Darlong, Joydeepa Doni, Shimelis N. Hagge, Deanna A. Halwai, Vikas John, Annamma Lambert, Saba M. Maghanoy, Armi Nery, Jose A. C. Neupane, Kapil D. Nicholls, Peter G. Pai, Vivek V. Parajuli, Pawan Sales, Anna M. Sarno, Euzenir Shah, Mahesh Tsegaye, Digafe Lockwood, Diana N. J. PLoS Negl Trop Dis Research Article Erythema nodosum leprosum (ENL) is a severe multisystem immune mediated complication of borderline lepromatous leprosy and lepromatous leprosy. ENL is associated with skin lesions, neuritis, arthritis, dactylitis, eye inflammation, osteitis, orchitis, lymphadenitis and nephritis. The treatment of ENL requires immunosuppression, which is often required for prolonged periods of time and may lead to serious adverse effects. ENL and its treatment is associated with increased mortality and economic hardship. Improved, evidence-based treatments for ENL are needed; however, defining the severity of ENL and outcome measures for treatment studies is difficult because of the multiple organ systems involved. A cross-sectional study was performed, by the members of the Erythema Nodosum Leprosum International STudy (ENLIST) Group, of patients with ENL attending seven leprosy referral centres in Brazil, Ethiopia, India, Nepal, the Philippines and the United Kingdom. We systematically documented the clinical features and type of ENL, its severity and the drugs used to treat it. Patients with chronic ENL were more likely to be assessed as having severe ENL. Pain, the most frequent symptom, assessed using a semi-quantitative scale was significantly worse in individuals with “severe” ENL. Our findings will determine the items to be included in a severity scale of ENL which we are developing and validating. The study also provides data on the clinical features of ENL, which can be incorporated into a definition of ENL and used for outcome measures in treatment studies. Public Library of Science 2015-09-09 /pmc/articles/PMC4564249/ /pubmed/26351858 http://dx.doi.org/10.1371/journal.pntd.0004065 Text en © 2015 Walker et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Walker, Stephen L. Balagon, Marivic Darlong, Joydeepa Doni, Shimelis N. Hagge, Deanna A. Halwai, Vikas John, Annamma Lambert, Saba M. Maghanoy, Armi Nery, Jose A. C. Neupane, Kapil D. Nicholls, Peter G. Pai, Vivek V. Parajuli, Pawan Sales, Anna M. Sarno, Euzenir Shah, Mahesh Tsegaye, Digafe Lockwood, Diana N. J. ENLIST 1: An International Multi-centre Cross-sectional Study of the Clinical Features of Erythema Nodosum Leprosum |
title | ENLIST 1: An International Multi-centre Cross-sectional Study of the Clinical Features of Erythema Nodosum Leprosum |
title_full | ENLIST 1: An International Multi-centre Cross-sectional Study of the Clinical Features of Erythema Nodosum Leprosum |
title_fullStr | ENLIST 1: An International Multi-centre Cross-sectional Study of the Clinical Features of Erythema Nodosum Leprosum |
title_full_unstemmed | ENLIST 1: An International Multi-centre Cross-sectional Study of the Clinical Features of Erythema Nodosum Leprosum |
title_short | ENLIST 1: An International Multi-centre Cross-sectional Study of the Clinical Features of Erythema Nodosum Leprosum |
title_sort | enlist 1: an international multi-centre cross-sectional study of the clinical features of erythema nodosum leprosum |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4564249/ https://www.ncbi.nlm.nih.gov/pubmed/26351858 http://dx.doi.org/10.1371/journal.pntd.0004065 |
work_keys_str_mv | AT walkerstephenl enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum AT balagonmarivic enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum AT darlongjoydeepa enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum AT donishimelisn enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum AT haggedeannaa enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum AT halwaivikas enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum AT johnannamma enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum AT lambertsabam enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum AT maghanoyarmi enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum AT neryjoseac enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum AT neupanekapild enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum AT nichollspeterg enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum AT paivivekv enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum AT parajulipawan enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum AT salesannam enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum AT sarnoeuzenir enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum AT shahmahesh enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum AT tsegayedigafe enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum AT lockwooddiananj enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum AT enlist1aninternationalmulticentrecrosssectionalstudyoftheclinicalfeaturesoferythemanodosumleprosum |